In order to determine the cellular distribution of androgen receptors (AR) in normal liver and to examine whether phenotypic changes occur in a variety of non-neoplastic liver diseases, cryostat sections of explanted livers removed from 52 consecutive patients undergoing orthotopic transplantation were immunostained using an anti-androgen receptor monoclonal antibody. In histologically normal liver, AR was immunolocalised to the nuclei of hepatocytes. The proportion of positive hepatocytes varied from about 50% to greater than 90%. Staining, ofvariable intensity, was restricted to parenchymal cells with no evidence of zonal heterogeneity with respect to labelling intensity. In tissue from patients with biliary cirrhoses and in some cases of alcoholic cirrhosis, labelling for AR was observed in areas of ductular metaplasia but not in areas of "typical" ductular reaction (ductular proliferation). Otherwise, no consistent abnormalities in immunolabelling were seen in any of the diseased livers. (JT Clin Pathol 1996;49:418-420) 
assays. Unfortunately, these techniques are both inaccurate and insensitive, because of the lability of the receptor protein, low levels of expression and the binding of androgens to albumin and sex hormone binding globulin.6 Indeed, a widely variable level of androgen receptor has been found and conflicting data from cytosolic and nuclear tumour fractions have made interpretation difficult. 7 Following the cloning and sequencing of the androgen receptor gene it is now possible to produce monoclonal antibodies directed against androgen receptor with modem molecular biological techniques. Such antibodies have been used in immunohistochemical studies of prostatic' and breast carcinoma' to investigate the significance of androgen receptor status. However, similar studies addressing androgen receptor protein expression in hepatocellular carcinoma have not been reported. Indeed, very little is known of the cellular distribution of the androgen receptor protein in normal liver or of any possible alterations of this in disease states, both neoplastic and nonneoplastic.
The aims of this study were to determine the cellular distribution of androgen receptors in normal liver and to examine whether phenotypic changes occur in a variety of non-neoplastic liver diseases.
At present, there is considerable interest in the role of androgens and their receptors in liver disease, particularly in the context of hepatocarcinogenesis. The incidence ofhepatocellular carcinoma in men greatly exceeds that in women' and the hepatocarcinogenic potential of oral anabolic androgens has been documented.2 In a rat model of hepatocarcinogenesis, treatment with anti-androgens reduced the size and number of tumours.3 Preliminary clinical trials suggest that drugs which inhibit the activity of sex steroids may control the growth and invasiveness of hepatocellular carcinomas in selected patients.4 Recently, the gender of the donor liver has been shown to influence outcome following orthotopic transplantation in adults: compared with male-male, male-female, and female-female donor-recipient gender combinations, female-male liver transplantation was associated with a significantly increased incidence of failure. 5 So far, detection of the human androgen receptor has relied heavily upon ligand binding Androgen receptors were demonstrated in 26 (53%) of 49 explanted livers with nonneoplastic pathology (table 1). In tissue from patients with biliary cirrhoses (primary biliary cirrhosis and primary sclerosing cholangitis) and in some cases of alcoholic cirrhosis, labelling for androgen receptors was observed in areas of ductular metaplasia but not in areas of "typical" ductular reaction (ductular proliferation). Otherwise, no consistent abnormalities in immunolabelling were seen in any of the diseased livers. No staining was observed in bile ducts infiltrated by inflammatory cells and no relation was seen-for example, in areas of piecemeal necrosis, between the hepatocyte staining intensity and the degree of inflammation. In those cases with demonstrable androgen receptors, the proportion of positive hepatocytes in any one case ranged from about 20% to greater than 90%. The mean age of androgen receptor positive and negative cases did not differ significantly (49 3 v 49 0 years, respectively). The proportion of female cases, as a whole, positive for androgen receptor was significantly greater than that for males (69-0 v 30 0%, p<002 x2 test with Yates' correction). Within individual diagnostic groups, however, the small numbers ofpatients precluded further statistical analysis. Discussion This is the first study to assess systematically the cellular distribution of androgen receptors in normal and diseased liver. Using ligand binding assays several authors have attempted to determine whether androgen receptor status is of prognostic or therapeutic importance in hepatocellular carcinomas and to assess how the expression of androgen receptor might alter during the progression from normality to malignancy.7 However, such studies have been inconclusive, reflecting both methodological problems and limited material. In this study expression of androgen receptors was found to be restricted to hepatocytes in both normal and diseased liver. By immunohistochemistry, no consistent abnormalities in androgen receptor expression were observed in non-neoplastic chronic liver diseases. Interestingly, androgen receptor expression was observed in a significantly greater proportion of women.
Recently Negro et al'0 developed a nonradioisotopic in situ hybridisation assay specific for the human androgen receptor mRNA. Although no normal liver was examined, androgen receptor mRNA was detected in eight (42%) of 19 non-neoplastic liver specimens, a similar proportion to that found in this study. Androgen receptor mRNA was similarly restricted to hepatocytes, although the proportion of reactive hepatocytes found was noticeably less than in the present study and was never more than 10%. This difference most probably reflects a difference in sensitivity of the two techniques. Indeed, in a test set of frozen sections from five hepatocellular carcinomas (HCCs) stained with a different androgen receptor monoclonal antibody, Negro et al were able to demonstrate androgen receptor protein in only one case, which also expressed androgen receptor mRNA. Two HCCs, strongly positive for the androgen receptor mRNA, were negative by immunohistochemistry and in the remaining two cases, neither androgen receptor protein nor its mRNA could be detected.
Several 
